Login



Forget your password?

Reimbursement guide

For over 17 years, Renassist® has partnered with healthcare providers to identify reimbursement solutions for patients with or without prescription drug coverage.

What are your patients paying for Renvela® (sevelamer carbonate)?

According to a survey of over 176,000 dialysis patients, over 50% of patients may pay less than $8.25/month for their Renvela® (sevelamer carbonate) prescriptions. Additionally, another 16% of patients have commercial insurance and may be eligible to pay $5 with the RenValue copay card. Where do your patients fit in?1

Prescription drug coverage mix (n=176,000)

Move your mouse around the pie chart to the left to learn cost savings facts. Click on a pie segment for more details on each insurance type.

  • Medicare Part D/Medicaid

    Patients with Medicare Part D and Medicaid pay less than $8.25 for a 90-day prescription with the Low-Income Subsidy (Extra Help).

  • Standard Medicare Part D

    Patients with Standard Medicare Part D could be eligible for Extra Help and lower their out-of-pocket costs.

  • Medicaid only

    The majority of state Medicaid plans cover Renvela®.

  • Commercial prescription insurance

    A coupon program could help lower the costs for people with commercial insurance coverage.

  • No prescription insurance

    The Renal Patient Assistance Program provides a 90-day supply of Renvela® (sevelamer carbonate) at no cost for qualified patients with no prescription drug coverage.

  • Other

    Other

  • 44%
  • 24%
  • 7%
  • 16%
  • 3%
  • 6%
  • Medicare Part D/Medicaid
  • Standard Medicare Part D
  • Medicaid only
  • Commercial prescription insurance
  • No prescription insurance
  • Other

Quick tips

Download a list of reimbursement tips to share with your patients.

Get the form

You only need one form to get started.
Download it now

Visit our website
Visit our website
Click here for Ferrlecit Important Safety Information and Full Prescribing Information

Visit our website
Click here for Hectorol Important Safety Information and Full Prescribing Information

Indication
Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information
  • Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel or Renvela tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please click here for full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).

Indication
Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are used to control phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information
  • Do not use sevelamer if you have a history of bowel obstruction.
  • Talk to your doctor if you have had difficulty swallowing or swallowing disorders; or if you have had digestive tract surgery or other digestive disorders, including severe constipation.
  • The most common side effects with sevelamer include vomiting, nausea, diarrhea, upset stomach, abdominal pain, flatulence, and constipation.
  • Cases of itching, rash, fecal impaction and, less commonly, slow bowel activity, bowel obstruction, and bowel perforation have been reported.
  • Uncommon cases of difficulty swallowing the Renagel or Renvela tablet have been reported. Talk to your doctor if you have difficulty swallowing medicines in tablet form. Renvela powder for oral suspension may be considered by your doctor if you have a history of difficulty swallowing.
  • Your doctor should monitor bicarbonate and chloride blood levels.
  • Reduced vitamins D, E, and K (clotting factors) and folic acid blood levels may be followed by your doctor.
  • Talk to your doctor when taking sevelamer with other medications.
  • Promptly contact your doctor if you experience severe abdominal pain, new or worsening constipation, or other severe intestinal symptoms while on sevelamer.
  • Take sevelamer with meals and adhere to your prescribed diet.

Please click here for full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).

Reference
1. Data on file, Sanofi US. August 2016.

    Terms and conditions  |  Privacy policy  |  Prescribing Information for Renvela®  |  Prescribing Information for Renagel®  |  Contact Renassist  |  Resources